Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases
$2bn Deal With $1.8bn Up Front For Idhifa Rights, Tibsovo And More
Agios’ cellular metabolism expertise first delivered cancer drugs but sees greater opportunity in genetically defined diseases. CEO Jackie Fouse talked to Scrip about the business strategy.
